INCY - Incyte: Undervalued And Expecting FDA Feedback In H2 2021
- Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations.
- According to the most recent quarterly report, Incyte Corporation appears to see that growth is returning to pre-covid levels.
- In 2025, if the FDA does not approve many more products, I would say that 2025 sales will be equal to $5.9 billion.
- Like other analysts, I expect FCF/Sales to increase from close to 9% in 2021 to more than 15% in 2025.
- Once investors learn about the incoming free cash flow generation, Incyte’s valuation could increase by more than 50%.
For further details see:
Incyte: Undervalued And Expecting FDA Feedback In H2 2021